For Paroxysmal Nocturnal Hemoglobinuria, the safety picture has become unusually specific, with major adverse vascular events reported at 2.7 per 100 patient years after starting complement inhibitor therapy and breakthrough hemolysis events clustering in low single digits when patients stay adherent and LDH is monitored. At the same time, the burden of treatment can shift dramatically, from an average of 26 eculizumab infusions per year to 6 with ravulizumab maintenance, while transfusion dependence often falls sharply. How these outcomes balance against rare but tracked meningococcal risks and ongoing follow up is where the real-world data gets most interesting.
Key Takeaways
- Real-world safety follow-up in complement inhibitor-treated PNH patients reports rare meningococcal infections when vaccination and prophylaxis protocols are followed, with counts reported in post-marketing assessments.
- Real-world data show that breakthrough hemolysis is relatively uncommon during C5 inhibition when patients are adherent to dosing and monitored with LDH.
- In registry data, infections other than meningococcus occur at measurable rates, reported as incidence proportions per patient-year in observational studies of complement blockade.
- The 2019/2020 EHA/ESC or guideline summaries recommend C5 inhibition for most PNH patients with evidence of hemolysis and/or high-risk clinical features, using criteria with quantitative biomarkers like LDH.
- In a real-world comparative analysis, patients treated with C5 inhibitors had markedly lower rates of breakthrough intravascular hemolysis compared with historical rates, with breakthrough events reported at low single-digit percentages.
- In the NEJM report of eculizumab, no patients in the treatment arm developed breakthrough hemolysis during the controlled evaluation period, yielding 0 breakthrough events in that phase.
- In clinical references, the choice between C5 inhibitors (eculizumab vs ravulizumab) often considers treatment burden, with ravulizumab’s longer interval (every 8 weeks maintenance) reducing infusion visits.
- The FDA approved ravulizumab (Ultomiris) for PNH on July 23, 2018.
- The FDA approved eculizumab (Soliris) for PNH on March 16, 2007.
- European Medicines Agency documents show Ultomiris received marketing authorization in 2018 following evaluation of its efficacy and safety in PNH.
- PNH is classified as a rare disease in the EU by Orphanet with a prevalence class of 1:10,000 to 1:50,000
- 0.18% of patients with aplastic anemia (AA) are reported to have PNH clones detectable by flow cytometry
- 23% of patients with PNH have bone marrow failure at diagnosis (as reported in a registry cohort)
- 51% of surveyed clinicians reported they use lactate dehydrogenase (LDH) to monitor hemolysis in PNH (survey-based)
- 5-year persistence with complement inhibitors reported at 60% in a claims database study (treatment continuity measure)
Real world data show rare meningococcal infections with adherence to vaccination and prophylaxis during C5 inhibitor therapy.
Related reading
01 · Category
Real World Evidence8 stats
01
Real-world safety follow-up in complement inhibitor-treated PNH patients reports rare meningococcal infections when vaccination and prophylaxis protocols are followed, with counts reported in post-marketing assessments.[1]
02
Real-world data show that breakthrough hemolysis is relatively uncommon during C5 inhibition when patients are adherent to dosing and monitored with LDH.[1]
03
In registry data, infections other than meningococcus occur at measurable rates, reported as incidence proportions per patient-year in observational studies of complement blockade.[2]
04
In real-world registries, C5 inhibitors are associated with reduced transfusion needs, with reported improvements for a majority of previously transfusion-dependent patients within follow-up windows.[3]
05
In PNH registries, thromboembolism rates after initiation of C5 inhibition fall to substantially lower annualized rates compared with historical pre-treatment periods (directionally quantified in registry reports).[2]
06
In a real-world study, patients receiving ravulizumab had fewer infusion visits compared with eculizumab due to the longer dosing interval, reducing the number of administrations per year.[2]
07
Patient-reported outcomes studies in PNH show measurable improvements in health-related quality of life after complement inhibitor treatment, reported using validated PRO instruments with numeric changes.[2]
08
In a cohort study, eculizumab treatment was associated with improved functional outcomes such as reduced fatigue scores over time, with quantitative changes reported in the publication.[2]
Interpretation
Real World Evidence Interpretation
Real world evidence from PNH registries and post marketing follow-up shows that with adherence to vaccination and monitoring, serious infections like meningococcal disease remain rare while key clinical outcomes improve, including fewer transfusion needs for most previously transfusion dependent patients and thromboembolism rates dropping to substantially lower annualized levels after starting C5 inhibitors.
02 · Category
Clinical Outcomes4 stats
01
The 2019/2020 EHA/ESC or guideline summaries recommend C5 inhibition for most PNH patients with evidence of hemolysis and/or high-risk clinical features, using criteria with quantitative biomarkers like LDH.[3]
02
In a real-world comparative analysis, patients treated with C5 inhibitors had markedly lower rates of breakthrough intravascular hemolysis compared with historical rates, with breakthrough events reported at low single-digit percentages.[4]
03
In the NEJM report of eculizumab, no patients in the treatment arm developed breakthrough hemolysis during the controlled evaluation period, yielding 0 breakthrough events in that phase.[5]
04
Patients on C5 inhibition therapy require meningococcal vaccination and adherence to prophylaxis protocols, and breakthrough meningococcal disease risk is a key safety outcome tracked in clinical guidance.[6]
Interpretation
Clinical Outcomes Interpretation
Across clinical outcomes, modern guidance and real world data show that C5 inhibition sharply reduces breakthrough intravascular hemolysis to low single digit rates compared with historical experience, and in the NEJM eculizumab evaluation phase there were 0 breakthrough hemolysis events, making the meningococcal safety monitoring and vaccination adherence an essential counterpart to these improved outcomes.
03 · Category
Treatment Regimens1 stats
01
In clinical references, the choice between C5 inhibitors (eculizumab vs ravulizumab) often considers treatment burden, with ravulizumab’s longer interval (every 8 weeks maintenance) reducing infusion visits.[5]
Interpretation
Treatment Regimens Interpretation
For Treatment Regimens in PNH, ravulizumab stands out because its maintenance dosing every 8 weeks can cut infusion visits compared with eculizumab, reflecting how longer intervals are a key factor when choosing between C5 inhibitors.
04 · Category
Market & Access7 stats
01
The FDA approved ravulizumab (Ultomiris) for PNH on July 23, 2018.[7]
02
The FDA approved eculizumab (Soliris) for PNH on March 16, 2007.[7]
03
European Medicines Agency documents show Ultomiris received marketing authorization in 2018 following evaluation of its efficacy and safety in PNH.[8]
04
The EMA EPAR for Soliris (eculizumab) documents its approval for PNH and includes clinical trial evidence supporting complement inhibition in this indication.[8]
05
PNH is a rare disease; the Orphanet database assigns PNH an Orphanet prevalence class indicating rarity in the EU, supporting orphan designation use in access programs.[9]
06
A UK NICE appraisal for eculizumab (TA438) includes a modeled population with QALY gain and cost inputs; the appraisal page provides numeric outcomes used in reimbursement decisions.[10]
07
A UK NICE appraisal for ravulizumab (TA523) includes numeric modeled QALY and cost-effectiveness results that influenced the final recommendation.[10]
Interpretation
Market & Access Interpretation
Across major regulators and health technology assessments, PNH market access has steadily strengthened since eculizumab’s 2007 FDA approval and has accelerated with ravulizumab reaching FDA approval in 2018, where EMA documentation and UK NICE models with quantified QALY and cost inputs supported reimbursement decisions for both therapies.
05 · Category
Epidemiology3 stats
01
PNH is classified as a rare disease in the EU by Orphanet with a prevalence class of 1:10,000 to 1:50,000[9]
02
0.18% of patients with aplastic anemia (AA) are reported to have PNH clones detectable by flow cytometry[3]
03
23% of patients with PNH have bone marrow failure at diagnosis (as reported in a registry cohort)[1]
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, PNH is rare in Europe at about 1 in 10,000 to 1 in 50,000, yet among related patients 0.18% of those with aplastic anemia have detectable PNH clones and 23% of people with PNH present with bone marrow failure, underscoring that while uncommon overall, it often clusters within this high risk hematologic setting.
06 · Category
Clinical Practice3 stats
01
51% of surveyed clinicians reported they use lactate dehydrogenase (LDH) to monitor hemolysis in PNH (survey-based)[11]
02
5-year persistence with complement inhibitors reported at 60% in a claims database study (treatment continuity measure)[12]
03
Mean annual number of infusions is 26 for eculizumab vs 6 for ravulizumab maintenance (derived from dosing intervals in real-world treatment patterns)[1]
Interpretation
Clinical Practice Interpretation
In clinical practice, clinicians most commonly rely on LDH for monitoring hemolysis in PNH, while real world data suggest strong treatment staying power with complement inhibitors at 60% over 5 years and dosing patterns that translate to substantially more frequent infusions with eculizumab, averaging 26 per year versus 6 for ravulizumab.
07 · Category
Outcomes4 stats
01
1.9 annualized thromboembolism events per 100 patient-years before complement inhibitor therapy in a registry cohort[13]
02
74% of previously transfusion-dependent patients became transfusion independent within 12 months after complement inhibitor initiation in a registry report[1]
03
In a real-world registry, the rate of major adverse vascular events (MAVE) was 2.7 per 100 patient-years after complement inhibitor initiation[14]
04
Eculizumab-treated patients had a hazard ratio of 0.04 for breakthrough hemolysis vs historical controls in an observational comparative study (relative risk reported)[15]
Interpretation
Outcomes Interpretation
From an outcomes perspective, complement inhibitor therapy in PNH shows clinically meaningful gains, including a sharp 0.04 hazard ratio for breakthrough hemolysis in eculizumab-treated patients and a 74% conversion to transfusion independence within 12 months, while major adverse vascular events remain at 2.7 per 100 patient-years and prior thromboembolism rates were 1.9 per 100 patient-years.
08 · Category
Patient Experience1 stats
01
63% of patients reported improvement in fatigue scores after complement inhibitor treatment as measured by validated patient-reported outcome scales (proportion with clinically meaningful improvement)[1]
Interpretation
Patient Experience Interpretation
In the patient experience category, 63% of Paroxysmal Nocturnal Hemoglobinuria patients reported clinically meaningful improvement in fatigue after complement inhibitor treatment based on validated patient-reported outcome scales.
09 · Category
Cost Analysis3 stats
01
U.S. list price for eculizumab is $— per vial (costing used in US payer budget impact models) as of 2024 pricing documentation[7]
02
In a cost model, monitoring costs (LDH tests and clinical visits) increased by 12% under Q8W ravulizumab compared with Q2W eculizumab when clinical follow-up schedules were applied[15]
03
Total direct healthcare costs decreased by 18% after initiating complement inhibitors in a retrospective claims analysis (pre-post cost change)[16]
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, using complement inhibitors led to an 18% drop in total direct healthcare costs in real-world pre versus post claims data, while Q8W ravulizumab still drove only a 12% increase in monitoring costs versus Q2W eculizumab when the follow-up schedules were applied.
10 · Category
Market Size1 stats
01
PNH complement inhibitor market expected to grow at 7.8% CAGR from 2024 to 2030 (industry forecast)[17]
Interpretation
Market Size Interpretation
The PNH complement inhibitor market is projected to expand at a 7.8% CAGR from 2024 to 2030, signaling steady growth in the Market Size outlook for therapies targeting paroxysmal nocturnal hemoglobinuria.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Thomas Lindqvist. (2026, February 13). Paroxysmal Nocturnal Hemoglobinuria Statistics. Gitnux. https://gitnux.org/paroxysmal-nocturnal-hemoglobinuria-statistics
MLA
Thomas Lindqvist. "Paroxysmal Nocturnal Hemoglobinuria Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/paroxysmal-nocturnal-hemoglobinuria-statistics.
Chicago
Thomas Lindqvist. 2026. "Paroxysmal Nocturnal Hemoglobinuria Statistics." Gitnux. https://gitnux.org/paroxysmal-nocturnal-hemoglobinuria-statistics.
Sources & references
17 sources cited across this report